MK-2206 (dihydrochloride)

[1]Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37.|[2]Agarwal E, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 2014 Mar 1;14:145.|[3]Li Yan, et al. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009.

ACS Omega. 2020 Feb 13;5 (7) :3709-3716.|ACS Omega. 2024 Dec 3;9 (50) :49739-49748.|Acta Otolaryngol. 2022 Jan;142 (1) :6-12.|Acta Pharm Sin B. 2021 Jan;11 (1) :71-88.|Acta Pharm Sin B. 2021 Jun;11 (6) :1592-1606.|Acta Pharmacol Sin. 2018 Nov;39 (11) :1787-1796.|Adv Sci (Weinh) . 2024 Jul;11 (26) :e2306348.|Adv Sci (Weinh) . 2024 Jun 3:e2400023.|Adv Sci (Weinh) . 2025 Feb 3:e2411719.|Aging (Albany NY) . 2021 Apr 11;13 (7) :10672-10687.|Aging. 2020 Jun 12;12 (12) :11717-11731.|Am J Cancer Res. 2021 Apr 15;11 (4) :1557-1571.|Angiogenesis. 2025 Feb 3;28 (2) :13.|Ann Transl Med. 2021 Apr;9 (7) :533.|Bioact Mater. 2022 Mar 24;18:116-127.|Biochem Biophys Res Commun. 2021 Jan 1:534:121-127.|Biochem Biophys Res Commun. 2022 Dec 17:634:152-158.|Biochem Biophys Res Commun. 2022 Jun 25;610:170-175.|Biochem Biophys Res Commun. 2024 Jun 1:723:150200.|Biochem Biophys Res Commun. 2025 Jan 16:749:151352.|Biochem Biophys Res Commun. 2019 Feb 26;510 (1) :97-103. |Biochem Pharmacol. 2025 Jul 26:241:117191.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar 2;1870 (4) :167111.|Biochim Biophys Acta Mol Basis Dis. 2024 Sep 3:167496.|Biol Trace Elem Res. 2023 Feb;201 (2) :843-855.|Biomaterials. 2024 Oct:310:122634.|Biomed Pharmacother. 2019 Dec;120:109498.|Biomed Pharmacother. 2021 Jan:133:111089.|bioRxiv. 2020 Jul 15.|bioRxiv. 2020 Mar.|bioRxiv. 2024 August 26.|bioRxiv. 2024 June 03.|bioRxiv. 2025 Feb 1:2025.01.30.635746.|bioRxiv. 2025 March 03.|bioRxiv. 2025 March 20.|Biosci Rep. 2019 Dec 20;39 (12) :BSR20191041.|BMC Cancer. 2024 Oct 7;24 (1) :1236.|Bosn J Basic Med Sci. 2021 Aug 1;21 (4) :434-446.|Br J Cancer. 2017 Sep 26;117 (7) :974-983.|Brain Dev. 2024 Feb;46 (2) :93-102.|Cancer Biol Ther. 2022 Dec 31;23 (1) :69-82.|Cancer Biol Ther. 2025 Dec;26 (1) :2442556.|Cancer Cell Int. 2021 Apr 26;21 (1) :235.|Cancer Cell Int. 2022 Jan 11;22 (1) :18.|Cancer Cell. 2018 Jun 11;33 (6) :1061-1077.e6. |Cancer Cell. 2025 Jul 15:S1535-6108 (25) 00271-5.|Cancer Lett. 2020 Apr 10;475:53-64.|Cancer Lett. 2021 Jul 28:511:1-14.|Cancer Lett. 2022 Oct 1:545:215826.|Cancer Lett. 2024 Jul 31:217147.|Cancer Res. 2021 May 1;81 (9) :2470-2480.|Cancer Sci. 2018 Apr;109 (4) :944-955. |Cancers (Basel) . 2023 Dec 12;15 (24) :5805.|Cell Commun Signal. 2024 Jun 10;22 (1) :318.|Cell Commun Signal. 2025 Apr 23;23 (1) :194.|Cell Commun Signal. 2025 Jun 13;23 (1) :280.|Cell Death Differ. 2021 Mar;28 (3) :1026-1040.|Cell Death Differ. 2023 Mar;30 (3) :825-838.|Cell Death Dis. 2018 Oct 3;9 (10) :1015. |Cell Death Dis. 2019 May; 10 (5) : 329.|Cell Death Dis. 2022 Apr 19;13 (4) :370.|Cell Death Dis. 2022 Sep 29;13 (9) :838.|Cell Death Dis. 2025 Oct 6;16 (1) :706.|Cell Death Dis. 2019 Aug 13;10 (8) :609. |Cell Death Discov. 2024 Jul 19;10 (1) :329.|Cell Immunol. 2022 Feb:372:104475.|Cell Mol Gastroenterol Hepatol. 2021;11 (3) :683-696.|Cell Oncol (Dordr) . 2021 Oct;44 (5) :1087-1103.|Cell Prolif. 2021 Jun;54 (6) :e13045.|Cell Rep. 2022 Dec 27;41 (13) :111891.|Cell Rep. 2023 Jan 31;42 (1) :111916.|Cell Reprogram. 2021 Dec;23 (6) :336-348.|Cell Signal. 2021 Apr:80:109900.|Cell Stem Cell. 2019 Dec 5;25 (6) :754-767.e9. |Cell Syst. 2020 Jan 22;10 (1) :66-81.e11.|Cell. 2014 Feb 13;156 (4) :771-85.|Cells. 2022 Nov 5;11 (21) :3505.|Chem Biol. 2012 Jan 27;19 (1) :140-54.|Clin Epigenetics. 2018 May 23:10:69.|Clin Exp Pharmacol Physiol. 2019 Sep;46 (9) :861-871.|Clin Exp Pharmacol Physiol. 2024 Apr;51 (4) :e13846.|Commun Biol. 2024 Nov 7;7 (1) :1459.|Commun Biol. 2025 Mar 31;8 (1) :529.|Curr Issues Mol Biol. 2024 Dec 31;47 (1) :16.|Curr Med Sci. 2022 Apr;42 (2) :387-396.|Cytokine. 2020 May;129:155046.|Department of Dental Pharmacology. Okayama University. 2015.|Department of Laboratory Medicine, Laboratory of Hematology of the Radboudumc and Radboud Institute for Molecular Life Sciences in Nijmegen, The Netherlands.2019 Oct.|Dev Growth Differ. 2016 Apr;58 (3) :280-92.|Development. 2024 Nov 1;151 (21) :dev202899.|Ecotoxicol Environ Saf. 2024 Jul 30:283:116804.|Elife. 2021 Jul 13:10:e66942.|Endocr Relat Cancer. 2019 Aug;26 (8) :699-712.|Eur J Cancer. 2022 May 19;170:91-102.|Eur J Pharmacol. 2019 May 15:851:69-79.|Exp Cell Res. 2020 Dec 1;397 (1) :112341.|Exp Eye Res. 2018 Jul:172:10-20.|Exp Ther Med. 2019 May;17 (5) :3530-3538. |Exp Ther Med. 2021 Oct;22 (4) :1082.|FASEB J. 2020 Jan;34 (1) :1481-1496.|FEBS J. 2019 Apr;286 (7) :1305-1318.|FEBS Open Bio. 2021 Jun;11 (6) :1659-1672.|Food Chem Toxicol. 2018 Oct:120:500-509.|Food Funct. 2021 May 11;12 (9) :3898-3918.|Free Radic Biol Med. 2022 Nov 20;193 (Pt 1) :304-318.|Front Cardiovasc Med. 2021 Sep 3;8:687540.|Front Cell Dev Biol. 2021 Apr 14:9:649277.|Front Microbiol. 2022 Sep 12:13:989183.|Front Mol Biosci. 2021 Jul 8:8:698975.|Genes Dis. 2021 Aug 17;9 (2) :562-575.|Graduate School of Arts & Sciences. Harvard University. 2016 Aug.|Harvard Medical School LINCS LIBRARY|Heliyon. 2024 Aug 10;10 (16) :e36017.|Heliyon. 2024 Oct 11;10 (21) :e39333.|Hum Mol Genet. 2017 Sep 15;26 (18) :3553-3563.|In Vitro Cell Dev Biol Anim. 2021 Sep;57 (8) :817-824.|Int Endod J. 2025 Sep 23.|Int Immunopharmacol. 2021 Apr:93:107395.|Int Immunopharmacol. 2021 Dec;101 (Pt A) :108264.|Int Immunopharmacol. 2024 Jul 19:139:112704.|Int Immunopharmacol. 2024 Oct 16;143 (Pt 2) :113399.|Int Immunopharmacol. 2024 Sep 18;142 (Pt B) :113186.|Int J Biochem Cell Biol. 2018 Apr:97:16-27.|Int J Biochem Cell Biol. 2018 Jun:99:43-51.|Int J Biol Macromol. 2024 Aug 26:135109.|Int J Biol Macromol. 2024 Nov 27:138168.|Int J Biol Macromol. 2024 Oct 30:137070.|Int J Biol Macromol. 2025 Dec;333 (Pt 2) :148750.|Int J Biol Macromol. 2025 May 15:144179.|Int J Biol Sci. 2021 Apr 24;17 (7) :1821-1836.|Int J Biol Sci. 2024 Oct 14;20 (14) :5548-5575.|Int J Clin Exp Med. 2016;9 (9) :18513-18518.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Endocrinol. 2024 Nov 12:2024:3494652.|Int J Med Sci. 2025 Jan 1;22 (1) :209-226.|Int J Mol Sci. 2022 Aug 8;23 (15) :8798.|Int J Mol Sci. 2023 Jul 6;24 (13) :11168.|Int J Oncol. 2017 Aug;51 (2) :625-632. |iScience. 2021 Sep 25;24 (10) :103173.|iScience. 2025 Oct 15.|iScience. 2025 Oct 27.|iScience. 2025 Sep 10;28 (9) :112919.|J Adv Res. 2025 May 13:S2090-1232 (25) 00343-1.|J Agric Food Chem. 2019 Sep 4;67 (35) :9805-9811.|J Agric Food Chem. 2022 Feb 16;70 (6) :1911-1922.|J Biochem Mol Toxicol. 2019 Nov;33 (11) :e22391.|J Biol Chem. 2012 Mar 23;287 (13) :9742-52.|J Biomed Sci. 2025 Jan 6;32 (1) :5.|J Cancer. 2018 Jun 14;9 (14) :2480-2491. |J Cell Biochem. 2018 May;119 (5) :3885-3891.|J Cell Biochem. 2019 Oct;120 (10) :17744-17756.|J Cell Biol. 2021 Oct 4;220 (10) :e202010118.|J Cell Mol Med. 2020 Jun;24 (12) :6869-6882.|J Cell Mol Med. 2021 Nov;25 (21) :10088-10100.|J Cell Mol Med. 2024 Apr;28 (7) :e18193.|J Cell Mol Med. 2024 Apr;28 (8) :1-11.|J Cell Mol Med. 2025 Jan;29 (1) :e70332.|J Cell Mol Med. 2025 Jan;29 (2) :e70352.|J Cell Physiol. 2021 Aug;236 (8) :5818-5831.|J Ethnopharmacol. 2021 Sep 15:277:114224.|J Ethnopharmacol. 2022 Apr 6:287:114937.|J Ethnopharmacol. 2024 Sep 13:118829.|J Ethnopharmacol. 2025 Mar 25:119707.|J Exp Clin Cancer Res. 2021 Aug 20;40 (1) :262.|J Exp Clin Cancer Res. 2021 Dec 10;40 (1) :390.|J Exp Clin Cancer Res. 2018 Apr 3;37 (1) :77. |J Exp Clin Cancer Res. 2019 Feb 13;38 (1) :76.|J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775.|J Immunol. 2020 Oct 15;205 (8) :2255-2264.|J Integr Neurosci. 2024 Jan 16, 23 (1), 14.|J Invest Dermatol. 2019 Jan;139 (1) :71-80.|J Lipid Res. 2024 Nov 15:100701.|J Mater Sci Technol. 13 August 2022.|J Mol Histol. 2019 Aug;50 (4) :369-374.|J Neuroinflammation. 2023 Feb 24;20 (1) :49.|J Neuroinflammation. 2024 Aug 2;21 (1) :192.|J Pain Res. 2020 Dec 1;13:3195-3206.|J Reprod Immunol. 2023 Jun:157:103928.|J Transl Med. 2022 Jul 21;20 (1) :325.|J Transl Med. 2023 Feb 3;21 (1) :74.|J Transl Med. 2024 May 14;22 (1) :457.|Lab Invest. 2024 Nov 28:102202.|Leuk Res. 2024 Jul 7:144:107548.|Life Sci Alliance. 2022 Jun 2;5 (10) :e202101330.|Life Sci. 2020 Mar 15;245:117328.|Life Sci. 2020 May 15;249:117503.|Life Sci. 2020 Nov 1;260:118470.|Life Sci. 2022 Nov 1:308:120907.|Lipids Health Dis. 2024 Dec 27;23 (1) :424.|Mechanobiol Med. 2025 Jul 28;3 (3) :100145.|Mediators Inflamm. 2019 Oct 7;2019:6168340.|Microbes Infect. 2025 May-Jun;27 (4) :105481.|Microvasc Res. 2024 Jul:154:104689.|Modern Oncology. 2017,25 (01) :0009-0013.|Mol Biol Rep. 2022 Jan;49 (1) :451-461.|Mol Cancer Res. 2024 Jul 2;22 (7) :668-681.|Mol Cancer Ther. 2024 Oct 1;23 (10) :1404-1417.|Mol Cancer Ther. 2025 Nov 20.|Mol Cancer. 2019 Nov 21;18 (1) :167. |Mol Carcinog. 2024 Sep;63 (9) :1827-1841.|Mol Carcinog. 2025 Jan;64 (1) :192-208.|Mol Cell Biochem. 2024 Sep;479 (9) :2365-2379.|Mol Cell. 2021 Jan 21;81 (2) :370-385.e7.|Mol Cell. 2022 Jul 21;82 (14) :2557-2570.e7.|Mol Cell. 2025 Apr 3;85 (7) :1411-1425.e8.|Mol Med Rep. 2022 Jan;25 (1) :17.|Mol Med Rep. 2024 Dec;30 (6) :213.|Mol Metab. 2024 Sep 19:102032.|Mol Oncol. 2022 Sep;16 (17) :3192-3209.|Mol Pharmacol. 2019 Dec;96 (6) :862-870.|Mol Ther Nucleic Acids. 2022 Jul 20:29:538-549.|Mol Ther Nucleic Acids. 2022 May 20:29:47-63.|Mol Cancer Res. 2020 Mar;18 (3) :414-423.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Nat Chem Biol. 2017 Jan;13 (1) :38-45.|Nat Commun. 2018 May 8;9 (1) :1816. |Nat Commun. 2020 Apr 14;11 (1) :1792.|Nat Commun. 2021 Jun 30;12 (1) :4050.|Nat Commun. 2022 Aug 2;13 (1) :4495.|Nat Commun. 2024 Jun 17;15 (1) :5144.|Nat Commun. 2024 Sep 6;15 (1) :7791.|Nat Struct Mol Biol. 2025 May;32 (5) :853-863.|Nature. 2018 Aug;560 (7719) :499-503.|Neurobiol Dis. 2019 Apr;124:520-530.|Nutrients. 2022 Aug 18;14 (16) :3395.|Oncogene. 2017 Aug 10;36 (32) :4585-4596.|Oncogene. 2018 Nov;37 (45) :5997-6009. |Oncogene. 2019 Jun;38 (26) :5250-5264.|Oncoimmunology. 2018 Aug 6;7 (10) :e1488565. |Oncol Lett. 2020 Dec;20 (6) :398.|Oncol Rep. 2019 Aug;42 (2) :849-856.|Oncol Res. 2024 Nov 13;32 (12) :1867-1879.|Oncotarget. 2016 May 17;7 (20) :29131-42. |Oncotarget. 2017 Jan 31;8 (5) :8536-8549. |Oncotarget. 2017 Jul 18;8 (29) :47642-47654. |Patent. US20140309249A1.|Patent. US20160368910A1.|Patent. US20190248778A1.|Patent. US20210236501A1.|Patent. US20220288067A1.|PeerJ. 2022 Oct 25:10:e14192.|Peptides. 2018 Sep:107:39-44.|Pharmacol Res. 2025 Dec:222:108027.|Phytomedicine. 2021 Nov:92:153687.|Phytomedicine. 2023 Jul:115:154833.|Phytomedicine. 2024 Jun 27:132:155846.|Phytomedicine. 2025 Dec:149:157560.|Platelets. 2023 Dec;34 (1) :2173505.|PLoS Biol. 2025 Sep 11;23 (9) :e3003362.|PLoS One. 2016 Jan 28;11 (1) :e0147682. |PLoS One. 2025 Apr 30;20 (4) :e0320154.|PNAS Nexus. 2024 Aug 13;3 (8) :pgae321.|Proc Natl Acad Sci U S A. 2016 Jul 26;113 (30) :E4338-47. |Proc Natl Acad Sci U S A. 2019 Feb 19;116 (8) :2996-3005. |Radiat Res. 2018 Aug;190 (2) :204-215. |Redox Biol. 2022 Feb:49:102217.|Redox Biol. 2025 Sep 16:87:103873.|Reproduction. 2022 Mar 10;163 (5) :241-250.|Research Square Preprint. 2020 Nov.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2023 May 5.|Research Square Print. August 22nd, 2022.|Ruperto Carola University Heidelberg. 2023 Jun 1.|Sci Adv. 2022 Jan 21;8 (3) :eabh2635.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Sci Rep. 2020 May 7;10 (1) :7714.|Sci Rep. 2022 Aug 13;12 (1) :13796.|Sci Rep. 2024 Dec 30;14 (1) :31935.|Sci Rep. 2024 Jun 24;14 (1) :14552.|Sci Rep. 2025 Mar 3;15 (1) :7448.|Sci Rep. 2025 Nov 27;15 (1) :43622.|Sci Rep. 2018 Oct 18;8 (1) :15454|Sci Total Environ. 2021 Nov 10;794:148732.|Sci Total Environ. 2024 May 22:935:173456.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Science. 2022 Jul 8;377 (6602) :eabg9302.|Sex Med. 2025 Aug 6;13 (4) :qfaf059.|Shock. 2023 Jul 1;60 (1) :100-109.|Signal Transduct Target Ther. 2021 Jun 18;6 (1) :234.|Small. 2025 Mar 19:e2412747.|SSRN. 2024|SSRN. 2025 Aug 6.|Stem Cell Res Ther. 2021 Jan 26;12 (1) :88.|Stem Cell Res Ther. 2022 Jan 10;13 (1) :13.|Stem Cell Res Ther. 2025 Feb 28;16 (1) :100.|Stem Cells. 2019 Dec;37 (12) :1567-1580.|Theranostics. 2020 Aug 6;10 (21) :9899-9912.|Theranostics. 2020 Feb 3;10 (6) :2859-2871.|Theranostics. 2021 Jan 19;11 (7) :3392-3416.|Theranostics. 2024 Jul 22;14 (11) :4481-4498.|Theranostics. 2024 Jun 17;14 (10) :3793-3809.|Theranostics. 2018 Feb 15;8 (7) :2044-2060. |Toxicol Appl Pharmacol. 2022 Apr 15:441:115969.|Toxicology. 2022 Oct;480:153326.|Transl Oncol. 2024 Dec:50:102146.|University of Colorado. 2025.|University of Otago. 2025 Oct 7.|Virology. 2022 Nov:576:83-95.|ACS Omega. 2023 Jun 16;8 (26) :23683-23694.|Acta Pharmacol Sin. 2023 Oct;44 (10) :2004-2018.|Adv Sci (Weinh) . 2025 May;12 (17) :e2408106.|Adv Sci (Weinh) . 2025 Sep 26:e02395.|Am J Physiol Gastrointest Liver Physiol. 2022 Aug 1;323 (2) :G102-G113.|Antioxidants (Basel) . 2022 Oct 18;11 (10) :2050.|Arch Biochem Biophys. 2023 May 15:740:109595.|Biochem Biophys Res Commun. 2023 Jan 1:638:14-22.|Biochem Biophys Res Commun. 2023 Nov 5:680:127-134.|Biochem Biophys Res Commun. 2025 May 16:771:152037.|Biochem Pharmacol. 2025 Aug 7;242 (Pt 3) :117212.|Biomed Pharmacother. 2024 Jan:170:116100.|Biomed Pharmacother. 2025 May 8:187:118136.|bioRxiv. 2023 May 14.|bioRxiv. 2024 Feb 8.|bioRxiv. 2025 Nov 3.|Blood Adv. 2023 Jul 11;7 (13) :3199-3212.|BMC Complement Med Ther. 2023 Oct 10;23 (1) :358.|Bone Res. 2025 Feb 24;13 (1) :25.|Bone. 2022 Jan:154:116231.|Br J Cancer. 2025 Jun 24.|Brain Res Bull. 2020 Sep;162:166-179.|Brain Res Bull. 2023 May:196:46-58.|Cancer Lett. 2023 Mar 1:556:216063.|Cancer Lett. 2024 Jun 1:591:216848.|Cancer Med. 2025 Sep;14 (18) :e71227.|Cancers. 2020 Jul 16;12 (7) :1918.|Carbohydr Polym. 2024 Feb 15:326:121637.|Cell Cycle. 2022 Dec;21 (24) :2590-2601.|Cell Death Dis. 2020 May 11;11 (5) :353.|Cell Death Discov. 2020 Jul 6;6:56.|Cell Mol Immunol. 2023 Feb;20 (2) :175-188.|Cell Rep. 2022 Feb 15;38 (7) :110392.|Cell Rep. 2023 Oct 17;42 (10) :113270.|Cell Rep. 2023 Sep 1;42 (9) :113048.|Cell Signal. 2024 Jan:113:110933.|Cell Signal. 2025 May 17:111877.|Cell Stress Chaperones. 2024 Apr;29 (2) :272-284.|Chem Biodivers. 2025 Oct 24:e02088.|Chem Eng J. 2025 Sep 7;522:168177.|Clin Exp Hypertens. 2023 Dec 31;45 (1) :2208777.|Cornell University. 2025|Cytotechnology. 2025 Apr;77 (2) :76.|Cytotherapy. 2023 Aug;25 (8) :858-865.|Ecotoxicol Environ Saf. 2024 Jan 1:269:115816.|Environ Toxicol. 2024 Jan;39 (1) :9-22.|Eur J Pharmacol. 2023 Oct 5:956:175957.|Eur J Pharmacol. 2024 Apr 5:968:176418.|Eur J Pharmacol. 2025 Jun 20:177871.|Exp Mol Med. 2022 Nov;54 (11) :2022-2035.|Exp Ther Med. 2022 Apr;23 (4) :301.|Exp Ther Med. 2022 Jun;23 (6) :413.|FASEB J. 2023 Feb;37 (2) :e22744.|FASEB J. 2025 May 31;39 (10) :e70619.|Food Chem Toxicol. 2025 Aug 14:205:115703.|Free Radic Biol Med. 2025 Oct 30:242:275-287.|Gastric Cancer. 2025 Oct 2.|Genes Dis. 2025 Nov 6.|Hematology. 2023 Dec;28 (1) :2214465.|Hum Reprod. 2024 Nov 1:deae246.|Indian J Pharm Sci. 2022.|Int Immunopharmacol. 2023 Jun:119:110247.|Int J Biochem Cell Biol. 2023 Feb:155:106359.|Int J Biol Sci. 2023 Jan 1;19 (1) :204-224.|Int J Mol Sci. 2023 Nov 22;24 (23) :16611.|Int J Mol Sci. 2025 Apr 26;26 (9) :4133.|Int J Radiat Oncol Biol Phys. 2025 Jun 16:S0360-3016 (25) 03903-3.|iScience. 2023 Apr 18;26 (5) :106688.|iScience. 2024 Mar 5;27 (4) :109358.|iScience. 2024 Oct 30;27 (12) :111290.|J Agric Food Chem. 2024 Jun 5;72 (22) :12516-12528.|J Biochem. 2024 Aug 8:mvae057.|J Biol Chem. 2022 Jun;298 (6) :102030.|J Biol Chem. 2023 Jan;299 (1) :102798.|J Biomed Mater Res A. 2021 Jun;109 (6) :1015-1026.|J Cancer. 2023 Mar 27;14 (5) :784-792.|J Diabetes Complications. 2025 Jun 22;39 (9) :109111.|J Ethnopharmacol. 2024 Feb 10:320:117393.|J Ethnopharmacol. 2025 Aug 27:354:120502.|J Ethnopharmacol. 2026 Feb 28:357:120890.|J Exp Clin Cancer Res. 2022 Jan 26;41 (1) :38.|J Exp Clin Cancer Res. 2023 Aug 10;42 (1) :204.|J Nanobiotechnology. 2022 Sep 24;20 (1) :422.|J Pharm Pharmacol. 2024 Mar 4;76 (3) :269-282.|J Transl Med. 2022 Nov 5;20 (1) :509.|J Transl Med. 2024 Sep 27;22 (1) :867.|J Transl Med. 2025 Sep 24;23 (1) :1011.|JCI Insight. 2025 Sep 23;10 (18) :e190716.|Life Sci. 2023 Oct 15:331:122001.|MedComm (2020) . 2024 Aug 12;5 (8) :e684.|Mol Biol Rep. 2023 Jan;50 (1) :319-329.|Mol Carcinog. 2023 Jul;62 (7) :963-974.|Mol Cell. 2025 Feb 20;85 (4) :843-856.e6.|Mol Med Rep. 2021 Jul;24 (1) :508.|Mol Med Rep. 2025 Oct;32 (4) :284.|Mol Oncol. 2023 Apr;17 (4) :664-685.|Mol Oncol. 2023 Sep;17 (9) :1803-1820.|Molecules. 2022 Dec 5;27 (23) :8568.|Nat Aging. 2024 Apr;4 (4) :568-583.|Nat Commun. 2022 Apr 19;13 (1) :2136.|Nat Commun. 2022 Nov 29;13 (1) :7345.|Nat Commun. 2023 Sep 28;14 (1) :6069.|Nat Commun. 2025 Mar 14;16 (1) :2528.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 24.|Oncogene. 2020 Oct;39 (41) :6451-6467.|Oncol Lett. 2023 Dec 18;27 (2) :59.|Oxid Med Cell Longev. 2022 Nov 18:2022:7862430.|Phytomedicine. 2022 Jul;101:154121.|Phytomedicine. 2023 Nov:120:155074.|Phytomedicine. 2023 Sep:118:154933.|Phytomedicine. 2025 Jun:141:156672.|R Soc Open Sci. 2020 Jul 8;7 (7) :200635.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2023 May 23.|Research Square Preprint. 2023 May 3.|Research Square Preprint. 2023 Oct 11.|Research Square Preprint. 2024 Mar 28.|Research Square Print. 2023 Mar 9.|Research Square Print. October 11th, 2022.|Sci Rep. 2025 Jul 2;15 (1) :23103.|Sci Rep. 2025 Nov 18;15 (1) :40619.|Sci Signal. 2023 May 16;16 (785) :eade8111.|Signal Transduct Target Ther. 2024 Mar 9;9 (1) :65.|SSRN. 2025 Nov 5.|SSRN. 2025 Oct 29.|Thorac Cancer. 2022 Jun;13 (12) :1772-1782.|Tissue Cell. 2025 Aug 29:97:103112.|Toxicol In Vitro. 2023 Dec:93:105698.|Transl Res. 2024 Apr:266:16-31.|Transplant Cell Ther. 2023 Aug;29 (8) :492.e1-492.e10.|University of Zürich. Department of Dermatology. 2021 Dec.